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Objective: Radiotherapy is planned to achieve the
optimal physical dose distribution to the target tumour
volume whilst minimizing dose to the surrounding normal
tissue. Recent in vitro experimental evidence has demon-
strated an important role for intercellular communication
in radiobiological responses following non-uniform expo-
sures. This study aimed to model the impact of these
effects in the context of techniques involving highly
modulated radiation fields or spatially fractionated treat-
ments such as spatially fractionated radiotherapy (GRID).
Methods: Using the small-animal radiotherapy research
platform as a key enabling technology to deliver precision
imaged-guided radiotherapy, it is possible to achieve
spatially modulated dose distributions that model typical
clinical scenarios. In this work, we planned uniform and
spatially fractionated dose distributions using multiple
isocentres with beam sizes of 0.5–5mm to obtain 50%
volume coverage in a subcutaneous murine tumour
model and applied a model of cellular response that
incorporates intercellular communication to assess the
potential impact of signalling effects with differ-
ent ranges.
Results: Models of GRID treatment plans which incorpo-
rate intercellular signalling showed increased cell killing
within the low-dose region. This results in an increase in
the equivalent uniform dose for GRID exposures com-
pared with standard models, with some GRID exposures
being predicted to be more effective than uniform
delivery of the same physical dose.
Conclusion: This study demonstrates the potential im-
pact of radiation-induced signalling on tumour cell re-
sponse for spatially fractionated therapies and identifies
key experiments to validate this model and quantify these
effects in vivo.
Advances in knowledge: This study highlights the unique
opportunities now possible using advanced preclinical
techniques to develop a foundation for biophysical
optimization in radiotherapy treatment planning.
INTRODUCTION
Radiotherapy treatment planning is based on the optimum
delivery of physical dose to a target tumour volume. With
the implementation of advanced conformal radiotherapy
techniques such as intensity-modulated radiotherapy and
stereotactic ablative radiotherapy into routine clinical
practice, tumour volumes can be targeted with un-
paralleled accuracy and often using image guidance.
In addition to conformal radiotherapy techniques, spatially
fractionated radiotherapy (GRID) delivers a single high
dose fraction to the target volume in a non-uniform pat-
tern, with subregions of the tumour exposed to high or low
doses.1 These are based on old approaches used to debulk
large tumours with minimal toxicity, but nowadays can be
delivered using advanced radiotherapy approaches through
either a custom GRID block,2–4 using a multileaf colli-
mator5 and most recently using helical tomotherapy
(TOMOGRID).6 GRID has been successfully used as part
of palliative and curative treatments of large head and neck
tumours, showing excellent initial response rates with low
toxicity.2,7
The complex, non-uniform dose distributions delivered
during GRID therapy may be of signiﬁcant importance to
the underlying radiobiological mechanism of response.
Using more simplistic approaches to generate non-uniform
dose distributions in vitro, focused on the impact of steep
dose gradients, our group has shown important con-
tributions of non-targeted radiobiological effects driven by
intercellular signalling, commonly known as bystander
effects.8,9 Although classically associated with low dose
exposures, recent results have shown large contributions of
signalling effects between cells exposed to high doses10 which
remain in contact for extended periods,11–14 with reports of
bystander cell killing of .50% and saturation doses .4Gy.13
These observations have been supported by mathematical
modelling studies which suggest that intercellular communica-
tion may have a signiﬁcant role in cell death even in populations
exposed to doses up to several Gy.15–18 Further evidence for
these effects has been obtained in small animal models, showing
effects of cell signalling in vivo for both tumour19 and normal
tissue response.20,21
However, whilst these experimental observations demonstrate
the effects of intercellular communication in vivo, their role in
tumour response following radiotherapy remains to be fully
determined. The limited accuracy and precision associated with
conventional preclinical radiation exposures has presented
technical challenges in providing sufﬁciently accurate quantiﬁ-
cation that is needed for the validation of predictive models.
With the implementation of precision image-guided radiother-
apy devices in radiobiology research laboratories,22,23 it is now
possible to systematically interrogate the physical parameters
and underlying biological response mechanisms associated with
heterogeneous radiation exposures and GRID.
This study aimed to simulate the impact of radiation-induced
signalling effects on tumour cell killing and effective dose dis-
tributions for a range of different spatially fractionated treat-
ment scenarios planned in small animal models. These
predictions may have important treatment planning implica-
tions for GRID and can be used to identify experiments needed
to determine the optimum parameters with which to validate
tumour response models using small animal image-guided
radiotherapy.
METHODS AND MATERIALS
Generation of treatment plans and dose calculations
Spatially fractionated treatment plans representative of typical
GRID beam conﬁgurations were generated in Muriplan (Xstrahl
Life Sciences, Camberley, Surrey, UK), a dedicated on-board
treatment planning system small animals based on the super-
position convolution algorithm.24
Plans were generated based on the cone-beam CTreconstruction
of a single representative subcutaneous tumour and aimed to
achieve 50–60% coverage of the tumour volume (155mm3)
using circular beam sizes of 0.5- and 1-mm diameter and square
ﬁelds of 33 3 and 53 5mm2. The number of isocentres and
geometric conﬁgurations varied depending on the aperture size.
The distance between the isocentres was in the range of 1mm
and different beam arrangements have been used as a function
of the beam size. For 0.5- and 1-mm circular beams, a hexagon
beam arrangement with 18 and 9 beams, respectively, was op-
timum to obtain 50% volume coverage. For 33 3- and 53 5-
mm2 beams, four and two isocentres were used to obtain similar
tumour coverage. Plans were generated with equal prescribed
doses at each isocentre using one beam per isocentre and then
normalized to deliver equal mean doses to the whole tu-
mour volume.
Cell response model
This work applies our published models describing cellular re-
sponses to modulated radiation ﬁelds incorporating cell cycling, cell
arrest and DNA damage induced by both direct radiation exposure
and indirect, cell signalling-mediated effects. Full descriptions of
the model and its validation in vitro have been previously
published16,17,25 and are brieﬂy summarized below for completeness.
DNA damage in cells is quantiﬁed as discrete “hits”, representing
potentially lethal damage. This damage can come about from two
sources—direct radiation exposure and intercellular communi-
cation. In direct radiation exposures, hits are induced in cells with
a Poisson distribution, with a mean number that is directly
proportional to the delivered dose. Intercellular signalling can
drive indirect signalling effects, where cells which respond to
signal exposure see the induction of additional damage events
which are treated identically to direct radiation-induced hits. The
probability of a cell responding is taken to be a function of the
time up to which it is exposed to these radiation-induced signals
above some response threshold. This probability is independent
of whether or not the cell was directly exposed to ionizing radi-
ation, meaning signalling-driven damage occurs both in and out
of ﬁeld. In cells which respond to signalling effects, the amount of
additional damage is taken to be Poisson distribution with
a mean, which is a characteristic of the cell line.
It is assumed that cells secrete signals that can induce damage
responses in neighbouring cells for a time proportional to the de-
livered dose. These signals are taken to be unstable, being removed
from the system with exponential kinetics. For an isolated system
(e.g. a tissue culture ﬂask), this gives a signal concentration which
initially builds to an equilibrium value before decaying away as cells
cease signalling. By modelling the kinetics of this exposure, the total
time for which cells are exposed to a given signalling level can be
calculated and in turn used to determine the probability that a cell
sees additional damage from signalling-driven effects.
These probabilities can be combined with the damage induced
by direct radiation exposure to calculate cell survival, on either
a cell-by-cell basis or population-level basis, and has been shown
to agree well with experimental observations.16,17 Radiobiolog-
ical response parameters for the DU-145 prostate cancer cell
model were used based on radiation response characteristics
determined in a previous work.17 These parameters were found
to accurately reproduce the in vitro survival response described
by the linear-quadratic parameters, a5 0.115, b5 0.026.
Three-dimensional signalling
In a more complex system, such as a heterogeneously irradiated
tissue, diffusion between subvolumes must also be taken into
account. In previous work, we have assumed simple linear dif-
fusion between neighbouring voxels,26,27 which is again applied
in this work.
Speciﬁcally, for each plan under consideration, the CT scan and
dose distribution obtained from the small-animal radiotherapy
research platform system were extracted as Nearly Raw Raster
Data (NRRD) ﬁles and imported into a custom MATLAB
(Mathworks Inc, Natick, MA, USA) program, which extracted
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the mouse target volume, as well as the dose delivered to each
voxel. Voxels within the mouse were then simulated as uni-
formly exposed cell populations, with signals being allowed to
diffuse between voxels within the mouse with a uniform diffu-
sion coefﬁcient. No signals were generated or diffused outside of
the mouse volume. The diffusion coefﬁcient within the mouse
was set to simulate different signal ranges—this is the maximum
distance from an irradiated volume at which a cell may see
a signalling-induced damage response, as described previously.27
For each irradiation condition and range, the level of survival has
been calculated for each voxel within the tumour volume and
compared with that predicted from a standard linear-quadratic
dose response, assuming no interaction between neighbouring
voxels. The dose which gives that level of survival in the linear-
quadratic model is deﬁned as the “signalling-adjusted dose”, for
ease of comparison between different dose–volume histograms
(DVHs). Speciﬁcally, signalling-adjusted doses are calculated as:
Dsig5
2a1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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where the signalling-adjusted dose for a given voxel, Dsig,
depends on the model-predicted survival for that voxel, S, and
the linear-quadratic parameters for uniform exposures a and b.
This value can be both greater than the physical dose (e.g. in
out-of-ﬁeld cells which see signalling from higher dose regions)
and lower than the physical dose (e.g. in small high-dose vol-
umes whose signals are spread over larger volumes) depending
on the physical beam geometry and signalling ranges.
These values were also converted into equivalent uniform doses
(EUDs) for comparison between different exposures. For a given
survival following a heterogeneous exposure, the EUD is the
dose which would lead to the same level of survival if delivered
uniformly to the whole volume. This is deﬁned as
e2aEUD2bEUD
2
5
1
N
+
N
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where the survival given by a dose of EUD is the same as the
average cross all N voxels within the tumour volume, each ex-
posed to a distinct dose Di.
RESULTS
In this study, physical dose histograms (DVHs) for GRID
treatments were designed to give an approximate tumour cov-
erage of 50% under different spatial conﬁgurations using beam
apertures from 0.5 to 5mm. An example of the dose dis-
tributions generated in Muriplan is shown in Figure 1a for 0.5-
mm isocentres along with the DVHs (Figure 1b) for each GRID
plan generated using different beam sizes. For small beam sizes
of 0.5 and 1mm, approximately 30% of the outlined volume
sees very low doses owing only to scattered radiation. In the
remaining volume, there is a smooth increase in dose, caused by
the large number of ﬁelds and high contribution of scatter owing
to the small ﬁeld sizes. This leads to highly heterogeneous dose
distributions, with 60% of the volume seeing less than the mean
dose and 10% of the volume seeing over three times the mean
dose. In comparison, for larger square 3- and 5-mm beams, the
DVHs show distinct structure, owing to the reduced number of
Figure 1. Treatment plans and dose–volume histograms (DVHs) for different spatially fractionated radiotherapy (GRID) beam
arrangements generated with field sizes 0.5, 1, 3 or 5mm: (a) Muriplan output for different GRID plans consisting of 16, 916, 9, 2 and 4
isocentres using a beam size of 0.5- and 1-mm diameter and 333- and 535-mm rectangular beams. The distance between
isocentres ranges between 0.5 and 1mm for the two beam geometries. Isodose lines show the 105% of prescribed dose in red
and 15% of prescribed dose in green. (b) Physical DVHs for uniform full coverage plan and GRID plans generated with field sizes of
0.5, 1, 3 or 5mm. All DVHs have been normalized to deliver the same average dose over the whole tumour.
Full paper: Preclinical modelling of spatially fractionated fields BJR
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ﬁelds and smaller scatter contribution in this scenario. Once
again, a large portion of the volume (;40%) sees only negligible
dose. Based only on physical dose, these cold spots should have
a high probability of containing surviving cells in all irradiations.
Impact of intercellular signalling on dose–volume
histogram for spatially fractionated radiotherapy
treatment plans
Figure 2a–d present the intercellular signalling-adjusted DVHs for
GRID plans with different beam sizes modelling various signalling
ranges from 0.5 to 5mm, with physical doses normalized to
a mean dose of 5Gy. As previously reported, at this dose,16 in-
tercellular communication drives a considerable component of
cell killing in low-dose regions. As a consequence, the largest
difference between physical and signalling-adjusted doses across
all beam sizes is in the low-dose regions, which only see negligible
physical dose. Incorporating signalling-driven effects into the plan
drives signiﬁcant cell killing in these regions, which is in turn
reﬂected in an increase in signalling-adjusted dose. Thus, in the
30–40% of the volume which receives a negligible physical dose,
the inclusion of longer signalling ranges begins to ﬁll in this dose
valley, effectively increasing the cell killing and signiﬁcantly re-
ducing the potential survival of cells within this region. The de-
pendence of this effect relies on the number and size of radiation
ﬁelds used: whilst signalling in the small low-dose regions be-
tween the many 0.5-mm ﬁelds saturates almost immediately, it is
not until ranges become comparable with the beam size that the
5-mm beams see a saturation of signalling effects.
For the highest dose regions, a small reduction in signalling-
adjusted is seen, as damaging signals fall off more quickly in the
heterogeneous scenario than the uniform exposure scenario
typically assumed in the linear-quadratic analysis.
Mean dose and equivalent uniform dose for spatially
fractionated radiotherapy treatment plans
Figure 3a shows the EUD for signalling in the 0–5-mm range
calculated from the dose cloud and contoured volume data
Figure 2. Impact of cell signalling on dose–volume histograms (DVHs) for different spatially fractionated radiotherapy (GRID) plans
generated using various beam sizes. Effective DVHs are produced for either 0-mm range (physical dose) or signalling ranges of 0.5,
1, 2 3 and 5mm for (a) 0.5-, (b) 1-, (c) 3- and (d) 5-mm beam size GRID. As signalling range increases, survival in the low-dose regions
of the tumour falls significantly, which is reflected in an increase in the effective dose delivered to this volume in all plans. This effect
is less rapid in large field plans, owing to the greater separation between beams.
BJR Butterworth et al
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output from Muriplan, normalized to a 5-Gy mean dose, and
Figure 3b shows the corresponding survival fraction. Owing to
increased survival in the low-dose region of the target, the EUD
in these plans is signiﬁcantly lower than the mean dose. The
EUD with no intercellular signalling varies with beam diameter:
for 0.5-mm beams, the calculated EUD is 0.58 of the mean dose
or 2.9 Gy, with a corresponding predicted survival fraction of
0.51, whilst 5-mm beams yield a survival of 0.55, corresponding
to a normalized EUD of 0.55 (2.75Gy).
However, when signalling is incorporated, cell killing in these
low-dose regions increases signiﬁcantly, reducing surviving
fraction and increasing EUD. There is a clear separation between
the small and large beam sizes, with a more rapid effect in the
former. This is due to the different irradiated volume, where the
many densely packed small ﬁelds see signiﬁcant signalling in
low-dose regions in the plans even at short signal ranges, whilst
longer signal ranges are needed to fully expose the whole tumour
to intercellular signalling for larger ﬁelds.
Small ﬁelds appear to cause systematically larger killing at all
ranges in these analyses, but this is primarily a result of differ-
ences in EUD for equal mean doses in the no-signalling cases. To
illustrate this, Figure 3c,d show the same results, but calculated
by normalizing the EUD in the no-signalling case to an equal
value, which in turn also gives identical survival in the absence
of signalling, and similar behaviours for different ﬁeld types at
high signalling ranges.
Signiﬁcantly, it can be seen that at high signalling ranges, the
normalized EUD is .1 indicating that these highly heteroge-
neous dose distributions are causing greater cell killing than
a uniform exposure delivering the same mean dose, even though
a large fraction of the volume sees little or no dose. This is in
stark contrast to traditional radiobiological models that assume
cellular independence28 and this may play an important role in
the effectiveness of highly modulated therapies. This has im-
portant implications not only for the delivery of effective
treatment regimens with modulated ﬁelds, but as yet undeﬁned
Figure 3. Impact of signalling range on calculated equivalent uniform doses (EUDs) and predicted surviving fraction. Changes in
EUD and survival are presented for plans, normalized to deliver either equal physical dose (a, b) or identical EUD (c, d) in the 0-mm
range case. For all conditions, incorporating signalling effects leads to a large increase in cell killing and corresponding increase in
EUD, driven by reduced survival in the low-dose region of the tumour. This effect occurs much more rapidly for small fields than for
exposures with fewer larger fields.
Full paper: Preclinical modelling of spatially fractionated fields BJR
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consequences for our understanding of long-term radiation risk
and mechanisms underpinning carcinogenesis where not only
cell death will be important.
Lastly, at very long ranges, it can be seen that the EUD begins to
trend down slightly, an effect which is driven by the gradual loss
of signals from the irradiated volume to the surrounding normal
tissue, somewhat reducing the cell kill expected for voxels ex-
posed to the highest doses.
DISCUSSION
The goal of preclinical radiotherapy studies is ultimately to
translate discovery through human trials and so, it is logical that
the preclinical studies should be motivated and designed to align
with a Phase 1 clinical trial. The capacity to model human ra-
diotherapy trials in mice is not a trivial task but has much
potential to provide further radiobiological understanding and
improve the basis upon which trials in humans are designed.22
The implication that the intercellular signalling effect plays an
important role at clinically relevant doses has previously been
investigated by McMahon et al.26 Applying this Monte Carlo
model of cellular radiation response to clinical plans resulted in
a distortion in the dose distribution in organs near treatment
ﬁelds, particularly in areas exposed to low doses.26 This largely
assessed the effects of intercellular signalling in the normal tissue
outside the tumour and led to the conclusion that bystander
signalling effects may play a more important role in relatively
parallel organs sensitive to lower dose regions. A relatively
smaller effect is typically seen in the high-dose regions that are
typically the constraints in therapy planning.
The present study uses the same model of intercellular signalling
effects but evaluates the effects within the tumour volume in the
context of GRID treatment plans. In the traditional radiobiology
paradigm that cells respond independently to ionizing radiation,
the large dose valleys in GRID plans are expected to signiﬁcantly
reduce EUD. However, applying the theoretical model presented
in previous work16,17 to different GRID treatment plans
increases cell killing within the low-dose bath, which results in
an increase in the EUD across the tumour. For some irradiation
conditions, this can lead to an EUD which is signiﬁcantly greater
than that achieved by uniformly delivering dose to the tumour.
Furthermore, the cell kill within the tumour shows a different
dependence on signalling range for different beam conﬁg-
urations, with smaller, more densely packed beams seeing much
more rapid increases in cell killing than the more widely spaced
larger beams. At high signalling ranges, the low-dose region in
both large and small beam plans sees signiﬁcant levels of cell
killing, and a small reduction in overall cell killing is seen in the
high-dose regions, although this has only a limited effect on the
total surviving fraction across the tumour as a whole.
Taken together, these effects indicate a potential approach to
quantify the range these signalling effects have through in vivo
preclinical radiobiological experiments, by comparing the effects
on in vivo survival of tumour cells for equal physical doses de-
livered using uniform exposures or modulated ﬁelds delivered
with small or large ﬁelds.
If signalling ranges are very short (,1mm), then the uniform
ﬁeld will cause signiﬁcantly greater cell killing than the modu-
lated ﬁelds. If signalling ranges are intermediate (approximately
0.5–2.5mm), small-ﬁeld modulated delivery will cause cell
killing similar to or greater than the uniform ﬁeld, whilst the
large ﬁelds will still see increased survival and reduced EUD.
Finally, for large signalling ranges (.3.5mm), all modulated
ﬁelds will be expected to see signiﬁcant increases in cell killing
and EUD, comparable with or greater than uniform exposures.
Whilst the present theoretical study identiﬁes a number of im-
portant potential impacts for radiation-induced signalling effects
on tumour response to spatially fractionated radiotherapy, sev-
eral other physical and biological factors may impact on tumour
response. These include uncertainties in dose delivery associated
with small ﬁeld sizes and positioning accuracy. In addition,
application of more advanced in vivo approaches using ortho-
topic or spontaneous tumour models that more accurately re-
capitulate aspects of the patient scenario would allow further
insight into the underlying radiobiological mechanisms of re-
sponse. Validating the scale of these effects in vivo will be an
important step in the rational design of future clinical
approaches which exploit these highly modulated exposures.
CONCLUSION
This study demonstrates the potential impact of radiation-
induced signalling for complex spatially fractionated radiother-
apy plans and also highlights how preclinical image-guided ra-
diotherapy platforms have the potential to meaningfully probe
the mechanisms of these effects, potentially providing invaluable
data to support the development of future clinical trials.
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